Cytophage Technologies (TSXV:CYTO) Debt-to-EBITDA : 0.00 (As of Dec. 2023)

View and export this data going back to 2024. Start your Free Trial

What is Cytophage Technologies Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Cytophage Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$0.00 Mil. Cytophage Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$0.00 Mil. Cytophage Technologies's annualized EBITDA for the quarter that ended in Dec. 2023 was C$12.80 Mil. Cytophage Technologies's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Cytophage Technologies's Debt-to-EBITDA or its related term are showing as below:

TSXV:CYTO' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.14 Med: -0.12 Max: 0.02
Current: 0.02

During the past 3 years, the highest Debt-to-EBITDA Ratio of Cytophage Technologies was 0.02. The lowest was -0.14. And the median was -0.12.

TSXV:CYTO's Debt-to-EBITDA is ranked better than
97.1% of 276 companies
in the Biotechnology industry
Industry Median: 1.34 vs TSXV:CYTO: 0.02

Cytophage Technologies Debt-to-EBITDA Historical Data

The historical data trend for Cytophage Technologies's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytophage Technologies Debt-to-EBITDA Chart

Cytophage Technologies Annual Data

Trend

Dec21

Dec22

Dec23

Debt-to-EBITDA

-0.09

-0.14

Cytophage Technologies Quarterly Data
	Dec21	Sep22	Dec22	Sep23	Dec23
Debt-to-EBITDA	N/A	-	0.01	-0.01	-

Competitive Comparison of Cytophage Technologies's Debt-to-EBITDA

For the Biotechnology subindustry, Cytophage Technologies's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cytophage Technologies's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cytophage Technologies's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Cytophage Technologies's Debt-to-EBITDA falls into.

Cytophage Technologies Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Cytophage Technologies's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0	+	0)	/	-0.136
	=	0.00

Cytophage Technologies's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0	+	0)	/	12.804
	=	0.00

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.

Cytophage Technologies (TSXV:CYTO) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Cytophage Technologies Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Cytophage Technologies's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Cytophage Technologies (TSXV:CYTO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytophage Technologies Ltd (TSXV:CYTO) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Cytophage Technologies Ltd is a Canadian biotechnology company that uses molecular genetic techniques and synthetic biology to create effective bacteriophages to address bacterial challenges affecting animal health, human health, and food security. Bacteriophages are viruses that have evolved to specifically target and destroy strictly bacterial cells and are safe for humans, animals, and plants. To combat dangerous bacteria company generates phages to address specific bacterial infections, including strains resistant to antibiotics. It has also developed a 'phage-display' methodology to develop vaccine-like products using bacteriophages for a number of potential applications in human and animal health.